New appointment at Affimed Therapeutics
This article was originally published in Scrip
Affimed Therapeutics (Germany) has appointed Dr Christian Hucke to take over responsibility for planning and implementation of the company’s clinical development programmes. He joins from Grünenthal, where he had the overall responsibility for a worldwide Phase III study in pain therapy of cancer patients, as well as a proof-of-concept Phase II study against diabetic polyneuropathy. Before that, Dr Hucke worked in clinical drug development at Paion Deutschland and the ClinPharmCologne TROPON. Affimed is a therapeutic antibody company developing therapeutics as treatments for life threatening diseases with high unmet medical need.